ArticleCancer immunology, immunotherapy : CII2021

Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.

Toshiki Kijima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.